Arch Venture Management’s Denali Therapeutics DNLI Stock Holding History

Arch Venture Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-381,249	Closed	-$7.82M	–	10
2024 Q1	$7.82M	Hold	381,249	–	–	9.75%	4
2023 Q4	$8.18M	Sell	381,249 -312,500	-45%	-$6.19M	5%	4
2023 Q3	$14.3M	Hold	693,749	–	–	9.3%	4
2023 Q2	$20.5M	Sell	693,749 -1,875,000	-73%	-$52.7M	12.64%	4
2023 Q1	$59.2M	Sell	2,568,749 -1,100,000	-30%	-$30.3M	28.57%	2
2022 Q4	$102M	Hold	3,668,749	–	–	26.13%	1
2022 Q3	$113M	Sell	3,668,749 -1,500,000	-29%	-$48.8M	14.6%	3
2022 Q2	$152M	Buy	+5,168,749	New	+$135M	18.54%	3

Other funds holding DNLI

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TPC

Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Arch Venture Management's DNLI Position: Q2 2024 in Review

Arch Venture Management sold out of Denali Therapeutics (DNLI) in Q2 2024, closing a stake of 381,249 shares — an estimated $7.82M sold.

Arch Venture Management first reported a position in DNLI in Q2 2022 and held it in 8 quarters. The position peaked at $152M in Q2 2022. 203 funds tracked by Wall St. Rank hold DNLI as of Q2 2024.

Arch Venture Management reported no remaining Denali Therapeutics position as of Q2 2024 after selling out during the quarter.
Arch Venture Management sold 381,249 Denali Therapeutics shares in Q2 2024, an estimated $7.82M.
Arch Venture Management first reported a position in Denali Therapeutics in Q2 2022 and held it in 8 quarters.
Arch Venture Management's Denali Therapeutics position peaked at $152M in Q2 2022.
203 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2024.

Based on Arch Venture Management's 13F filing for Q2 2024, filed 14 Aug 2024.